Pricing

Decibel Therapeutics Inc (DBTX)

followers ·
Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
CEO:
Laurence E. Reid
Employees:
60
1325 BOYLSTON STREET, SUITE 500, BOSTON, MA, 02215
617-370-8701
Decibel Therapeutics, Inc. engages in discovering and developing transformative treatments for hearing and balance disorders. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO and AAV.201 to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available